Table 1 Information on the clinical trials eligible for enrollment and their specific characteristics
Author | Year | Country | Trial design | Total patients | STK11mut patients | Patients with KRASmut and STK11mut | Patients with KRASmut and STK11wt | Stage | Treatment | Multivariable HR of PFS | Multivariable HR of OS | Total STK11mut patients treated with ICIs | CR/PR STK11mut patients treated with ICIs | Total STK11wt patients treated with ICIs | CR/PR STK11wt patients treated with ICIs | Total STK11mut patients detected PD-L1 | STK11mut patients with PD-L1 ≥ 50% | STK11mut patients with PD-L1 ≥ 1% and < 50% | STK11mut patients with PD-L1 < 1% | Total STK11wt patients detected PD-L1 | STK11wt patients with PD-L1 ≥ 50% | STK11wt patients with PD-L1 ≥ 1% and < 50% | STK11wt patients with PD-L1 < 1% | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Yoh K | 2021 | Japan | RA | 832 | 52 | 11 | NA | II to IV or recurrent | CT, ICIs | NA | NA | 18 | 0 | 242 | 19 | 52 | 9 | 21 | 22 | NA | NA | NA | NA | 7 |
Facchinetti F | 2017 | France | RA | 302 | 25 | 13 | NA | II to IV | S, CT, RT | 1.33 (95%: CI: 0.83–2.12) | 1.31 (95% CI: 0.80–2.14) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 8 |
Xu M | 2021 | China | RA | 447 | 27 | NA | NA | IA-IIIB | S, CT | NA | 1.046 (95% CI: 0.6975–1.256) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 8 |
Abu Hejleh T | 2021 | USA | RA | 70 | 11 | 3 | 11 | III | S, CT, RT, ICIs | 2.25 (95% CI: 1.03–4.88) | NA | NA | NA | NA | NA | 8 | 1 | 2 | 5 | 32 | 10 | 6 | 16 | 9 |
Ascierto ML (a)* | 2021 | USA | RA | 181 | 17 | 10 | 47 | III/IV | CT, ICIs | NA | NA | 17 | 1 | 164 | 34 | NA | NA | NA | NA | NA | NA | NA | NA | 9 |
Ascierto ML (b)* | 2021 | USA | RA | 121 | 26 | 14 | 24 | III/IV | CT, ICIs | NA | NA | 26 | 1 | 95 | 19 | NA | NA | NA | NA | NA | NA | NA | NA | 9 |
Shire NJ (c)* | 2020 | USA | RA | 270 | 40 | 17 | NA | IV | ICIs, CT | NA | NA | 34 | 14 | 200 | 89 | NA | NA | NA | NA | NA | NA | NA | NA | 8 |
Shire NJ (d)* | 2020 | USA | RA | 670 | 111 | 56 | NA | IV | ICIs, CT | NA | NA | 73 | 18 | 420 | 143 | NA | NA | NA | NA | NA | NA | NA | NA | 8 |
Cardona AF | 2022 | Colombia | RA | 204 | 90 | 36 | 35 | advanced | ICIs, CT | 1.31 (95%CI: 1.12–1.88] | 1.33 (95%CI: 1.13–2.21) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 8 |
Heymach JV | 2021 | USA | RA | 164 | 12 | 7 | 44 | III | definitive RT, CT | 2.53 (95%CI: 1.375–4.657) | 2.198 (95%CI: 1.097–4.405) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 8 |
Albacker LA | 2018 | USA | RA | 174 | 54 | NA | NA | IV | ICIs, CT | NA | NA | 11 | 0 | 55 | 19 | 54 | 11 | 43 | 120 | 55 | 65 | 9 | ||
Wang H | 2021 | China | RA | 598 | 60 | NA | NA | IIIB/IV | ICIs, CT | 1.391 (95%CI: 1.048–1.845) | 1.567; (95%CI: 1.160–2.119) | NA | NA | NA | NA | 60 | 5 | 17 | 38 | 538 | 85 | 208 | 255 | 9 |
Hong YC | 2022 | China | RA | 125 | 43 | NA | NA | I/II/III | S, CT | NA | 2.314 (95%CI: 1.248–4.290) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 7 |
Girodet PO | 2022 | France | RA | 159 | 37 | 24 | 49 | Locally advanced /metastatic disease | ICIs, CT | 1.87 (95% CI: 1.21–2.89) | 2.26 (95% CI: 1.35–3.79) | NA | NA | NA | NA | 37 | 8 | 12 | 17 | 120 | 46 | 35 | 39 | 9 |